Soliton

Soliton is developing game-changing science to address multiple multibillion-dollar market opportunities. They spent over 25 million dollars over the past 5 years developing a breakthrough technology that dramatically accelerates the removal of tattoos. Their devices use very high energy, in the range of 3,000 volts at nearly 3,000 amps, to form acoustic shockwaves at 100 times per second.  Soliton's core team is comprised of life science veterans, with more than 150 years of life science experience, multiple device clearances, and multiple national and international aesthetic device launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

IRVINE, Calif., Dec. 16, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ: SOLY).

Allergan Aesthetics Completes Acquisition of Soliton

The company's absorption into AbbVie will apparently occur very, very soon.

Why Soliton Popped While the Market Slid Today

Aerpio Pharmaceuticals Inc

Chiasma

Net Element

1Life Healthcare

Sykes Enterprises

NEW YORK , July 10, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 1Life Healthcare, Inc. (NASDAQ: ONEM)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Iora Health. Under the terms of the merger, 1Life Healthcare will acquire Iora Health in an all-stock transaction.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm

NEW YORK, May 15, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Soliton, Inc. ("SOLY" or the "Company") (SOLY) relating to its proposed acquisition by Allergan Aesthetics, an AbbVie company. Under the terms of the agreement, SOLY shareholders will receive $22.60 in cash per share.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Soliton, Inc. - SOLY

Soliton (SOLY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Soliton (SOLY) is in Overbought Territory: What's Next?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Soliton, Inc. (NasdaqGS: SOLY) to AbbVie, Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Soliton will receive only $22.60 in cash for each share of Soliton that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whet

SOLITON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Soliton, Inc. - SOLY

HOUSTON, May 12, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today reported financial results for the first quarter ended March 31, 2021. Recent Company Highlights: Received FDA 510(k) clearance for short-term improvement in the appearance of cellulite; Selected RESONIC™ as the brand name for the Company's Rapid Acoustic Pulse (RAP) device; Received FDA Special 510(k) clearance for modifications to the RESONIC device to facilitate ease of use in commercial settings; Successfully completed all required safety testing including Quality System/Current Good Manufacturing Practice regulations for medical devices (21 CFR Part 820) inspection from the FDA; Expanded sales team through appointment of Sean J.

Soliton Reports First Quarter 2021 Results

MILWAUKEE, May 10, 2021 /PRNewswire/ -- Ademi LLP is investigating Soliton (NASDAQ: SOLY) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click here to learn how to join the action: https://www.ademilaw.com/case/soliton-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Soliton, Inc. has obtained a Fair Price in its transaction with AbbVie

NEW YORK, May 10, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Soliton, Inc. ("Soliton" or the "Company") (NASDAQ: SOLY) in connection with the proposed acquisition of the Company by Allergan Aesthetics, an AbbVie company (NYSE: ABBV). Under the terms of the merger agreement, Allergan Aesthetics will pay Soliton shareholders $22.60 in cash for each Soliton share that they own.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Soliton, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Soliton, Inc. (NASDAQ: SOLY) to Allergan Aesthetics for $22.60 per share in cash is fair to Soliton shareholders. Halper Sadeh encourages Soliton shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Soliton an

Soliton Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Soliton, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SOLY

The stock price of Soliton Inc (NASDAQ: SOLY) increased by over 20% during intraday trading. This is why it happened.

SOLY Stock: Over 20% Increase Intraday Explanation

AbbVie Inc (NYSE: ABBV) is making an opportunistic play to boost the aesthetics business by adding a long-delayed body sculpting product into the fold. AbbVie's Allergan Aesthetics unit will pay $550 million in cash to scoop up Soliton Inc (NASDAQ: SOLY) and Resonic, its sound-wave device that improves the appearance of cellulite.

Soliton Stock Rallies After $22.60/Share Buyout From AbbVie

IRVINE, Calif. and HOUSTON, May 10, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and Soliton (NASDAQ: SOLY) today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONICTM, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite.

Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio

HOUSTON, May 5, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced the launch of its highly anticipated Rapid Acoustic Pulse™ (RAP) device — RESONIC™. The dual-platform RESONIC™ device utilizes a first-of-its-kind technology and offers a paradigm-shifting approach to two in-demand procedures: tattoo removal and cellulite treatment.

Introducing RESONIC™

HOUSTON, May 4, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the Company is scheduled to release its first quarter 2021 financial results on Thursday, May 13, 2021, before market open. Soliton will host a conference call on Thursday, May 13, 2021, at 4:30 p.m.

Soliton to Report First Quarter 2021 Financial Results on May 13, 2021

HOUSTON, April 29, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced the U.S. Food and Drug Administration ("FDA") clearance of the Company's special 510(k) for modifications to its RESONIC™ device. "We were thrilled to receive this clearance as it marks the last significant hurdle to our ability to initiate our commercial launch of the improved RESONIC device in the second quarter," stated Brad Hauser, Soliton CEO and President.

Soliton Receives FDA Clearance of Special 510(k)

HOUSTON, April 27, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the 52-week results from its pivotal cellulite trial have been accepted for an oral presentation at the American Society for Laser Medicine and Surgery Virtual Annual Conference, held May 15-16, 2021. "We are honored to present new long-term cellulite data at the ASLMS annual conference.

Soliton Announces Oral Presentation at American Society for Laser Medicine and Surgery Virtual Annual Conference

HOUSTON, April 15, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the U.S. Food and Drug Administration ("FDA") has accepted its special 510(k) application previously submitted on March 31, 2021 for modifications to RESONIC™ device planned for commercial launch as complete. The company expects to hear if the FDA has cleared its special 510(k) application in the next 15-20 days unless the process takes slightly longer than normal given the COVID-related workload inside the FDA.

Soliton Provides Special 510(k) and Commercialization Update

HOUSTON, March 11, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced members of management will be presenting at three upcoming healthcare conferences. Event: 33rd Annual Virtual ROTH Conference Format: Presentation & 1x1 Meetings Date: March 15 – 17, 2021 Presentation: Presentation will be available on-demand beginning on Monday, March 15, 2021 at 9am ET Location:      Webcast Link Event: Oppenheimer 31st Annual Healthcare Conference Format: Presentation & 1x1 Meetings Date: Tuesday, March 16, 2021 Time: 4:30pm – 5:00pm ET Location:      Webcast Link Event: Maxim 2021 Emerging Growth Virtual Conference Format: Presentation Date: March 17 – 18, 2021 Presentation: Presentation will be available on-demand beginning on Wednesday, March 17, 2021 at 9:00 a.m.

Soliton to Participate in Three Upcoming Healthcare Conferences

HOUSTON, March 9, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced that the company initiated a second pre-clinical study in animals for potential treatment of liver fibrosis intending to validate the first animal study that demonstrated positive results for the potential treatment of liver fibrosis. This additional pre-clinical study will seek to confirm the positive findings of Soliton's initial pre-clinical study in animals.

Soliton Announces Initiation of Second Animal Study for Potential RAP Treatment of Liver Fibrosis

Soliton, Inc. (SOLY) CEO Brad Hauser on Q4 2020 Results - Earnings Call Transcript

HOUSTON, March 4, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Company...

Soliton Reports Fourth Quarter and Full Year 2020 Results

HOUSTON, Feb. 22, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the Company is scheduled to release its fourth quarter and full year 2020 financial results on...

Soliton to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

HOUSTON, Feb. 18, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the company's Rapid Acoustic Pulse (RAP) device received the Best New Technology Award from...

Soliton Named Best New Technology Award at the Aesthetic Industry Association Board Meeting

HOUSTON, Feb. 1, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Rapid Acoustic Pulse...

News for Soliton Stock (SOLY)